Norcantharidin tablets
Function and Efficacy
In vitro animal tests showed that this product had a destructive or inhibitory effect on the morphology or proliferation of liver cancer BEL-7402, esophageal cancer CaEs-17, laryngeal cancer SMMC-7721, cervical cancer Hela and other cell lines. In vivo tests showed a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma 180 and solid liver cancer. It can increase the respiratory control rate and lysosomal enzyme activity of tumor cell microsomes in ascites liver cancer H22 mice, inhibit cancer cell DNA synthesis, and destroy cancer cell skeleton and ultrastructure. It interferes with cancer cell division, blocks it in the M phase, and affects its cycle speed, destroying the cancer cell skeleton (microfilaments, microtubules), affecting the ultrastructure of cancer cells, causing damage to mitochondria, microvilli and plasma membrane, etc., blocking the M phase of the cell division cycle and interfering with cancer cell division.
Ingredients
Norcantharidin.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| NorcantharidinIngredients |
In vitro animal tests have a destructive or inhibitory effect on the morphology or proliferation of liver cancer BEL-7402, esophageal cancer CaEs-17, laryngeal cancer SMMC-7721, cervical cancer Hela and other cell lines. In vivo tests have a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma 180 and solid liver cancer, and can increase the respiratory control rate and lysosomal enzyme activity of tumor cell microsomes of ascites liver cancer H22 mice, inhibit cancer cell DNA synthesis, destroy cancer cell skeleton and ultrastructure, interfere with cancer cell division and block at M phase, and affect its cycle speed, destroy cancer cell skeleton (microfilaments, microtubules), affect cancer cell ultrastructure leading to mitochondrial, microvilli and plasma membrane damage, block the M phase of cell division cycle and interfere with cancer cell division. More |
5442-12-6 | 3 |
Appearance
This product is a sugar-coated tablet, which appears white after removing the coating.
Indication
Anti-tumor drug. Used for liver cancer, esophageal cancer, stomach and cardia cancer, as well as leukopenia, hepatitis, cirrhosis, hepatitis B virus carriers. It can also be used as preoperative medication or in combined chemotherapy.
Usage and Dosage
Oral administration. 5-15 mg once, 3 times a day. Start with a small dose and gradually increase the dose. A higher dose can be used for advanced patients, and a reduced dose can be used for children. The course of treatment is one month, and generally 3 courses can be maintained. This product can be used alternately with sodium norcantharinate injection. However, it is not advisable to use the drugs together at the same time.
Adverse Reactions
Some patients may experience symptoms such as nausea, vomiting, and dizziness, which can disappear on their own by stopping the medication, reducing the dosage, or taking symptomatic treatment.
Precautions
Not yet clear
Special Population Medication
Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.
Drug Interactions
Not yet clear.
Storage
Keep sealed.
Packaging Specification
5mg
Validity Period
Tentative 24 months
Manufacturer
Shandong XinYi Pharmaceutical Co., Ltd.
-
Founded in:
2013-04-09 -
Address:
No. 1 Xingping Road, Pingyuan County -
Tax NO.:
91371426065926234K -
Registered Funds:
177.40615851 million yuan -
Website:
-
Email: